• PDF: Delivered by email usually within 48 UK business hours.

Emisphere Technologies, Inc. (EMIS) - Pharmaceuticals & Healthcare
Deals and Alliances Profile

  • Publication Date:March 2011
  • Publisher:GlobalData
  • Product Type: Report
  • Pages:136

Emisphere Technologies, Inc. (EMIS) - Pharmaceuticals & Healthcare Deals and Alliances Profile

Emisphere Technologies, Inc. (EMIS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Emisphere Technologies, Inc. (Emisphere) is a biopharmaceutical company which focuses on enhanced delivery and absorption of therapeutic molecules and pharmaceutical compounds applying its proprietory eligen technology. The eligen technology can be applied to the oral route of administration, as well as to other delivery pathways, such as inhalation, buccal, transdermal, intra-vaginal, rectal or facilitate in the transport of therapeutic macromolecules such as proteins, peptides, and polysaccharides, and poorly absorbed small molecules across biological membranes, such as the small intestine. The company has many products in its pipeline at various developmental stages including nutritional supplements and injectable harmones. Emisphere has also established partnership agreements with Novo Nordisk A/S, Novartis Pharma AG and Genta, Inc. to support its developmental platform and commercialise the products. The company is headquartered at Cedar Knolls in New Jersey, the US.

Emisphere Technologies, Inc. (EMIS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you an in-depth data and trend analysis of the company's mergers and acquisitions (M&A) and financings. The report provides detailed information on M&A, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions registered by the company over a five year period. The report portrays detailed comparative data on the number of deals and their value subdivided by deal types, markets, and regions, besides highlighting the company's major recent financial deals.

Data presented in this report was derived from GlobalData's proprietary in-house Pharmaceuticals and Healthcare eTrack deals database and primary and secondary research.

Scope

  • Financial Deals - Analysis of the company's financial deals including M&A, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
  • Deals by Year - Chart and table displaying information on the number of deals and value reported by the company by year, for a five year period.
  • Deals by Type - Chart and table depicting information on the number of deals and value reported by the company by type such as M&A, Equity/Debt Offering etc.
  • Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region for North America, Europe, the Middle East and Africa and South and Central America.
  • Deals by Market - Chart and table showing information on the number of deals and value reported by the company, by market.
  • Major Recent Deals - Information on the company's major recent financial deals. Each such deal has a brief summary, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
  • Business Description - A brief description of the company's operations.
  • Key Employees - A list of the key executives of the company.
  • Important Locations and Subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key Competitors - A list of key competitors of the company.
  • Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements.

  • The profile analyzes the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divesture strategy

  • Deals are presented from the company's core business segments' perspective to help you understand its corporate strategy

Access detailed information about the company's recent financial deals that enables you to understand the key deals which have shaped the company

  • Major recent deals are presented in detail, which provides information on each deal's brief summary, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company to identify potential customers and suppliers.

  • The profile analyzes the company's business structure, locations and subsidiaries, key executives and their biographies and key competitors.

Stay up to date on the major developments affecting the company

  • Recent developments in the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research.

  • Key elements such as break up of deals by categories and information on detailed major deals are incorporated in the profile to assist your academic or business research needs.
  • Emisphere Technologies, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
    • Emisphere Technologies, Inc., Pharmaceuticals & Healthcare Deals By Type, 2005 to YTD 2011
    • Emisphere Technologies, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011
    • Emisphere Technologies, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2005 to YTD 2011
    • Emisphere Technologies, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Emisphere Technologies, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Emisphere Technologies, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Emisphere Technologies, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Emisphere Technologies, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Emisphere Technologies, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2005 to YTD 2011
    • Emisphere Technologies, Inc., Pharmaceuticals & Healthcare, Deal Details
    • Partnerships
    • Emisphere Technologies Enters Into Research Collaboration With Alchemia
    • Emisphere Technologies Enters Into Co-Development Agreement With AAIPharma
    • Emisphere Enters Into Research and Collaboration Agreement With Roche
    • Licensing Agreements
    • Emisphere Enters Into Licensing Agreement With Novartis Pharma
    • Emisphere Technologies Enters Into Licensing Agreement With Novo Nordisk
    • Emisphere Technologies Enters Into Licensing Agreement With Novo Nordisk
    • Genta Signs Licensing Agreement With Emisphere Technologies
    • Equity Offering
    • Emisphere Technologies Completes Private Placement Of $3.5 Million
    • Emisphere Technologies Completes Private Placement Of $3.5 Million
    • Emisphere Technologies Completes Registered Direct Offering Of $4 Million
    • Emisphere Technologies Completes Private Placement Of $4 Million
    • Emisphere Technologies Completes Registered Direct Offering Of $7.6 Million
    • Emisphere Completes Private Placement Of $33 Million
    • Emisphere Technologies Completes Private Placement Of $15.74 Million
    • Divestiture - Assets
    • Emisphere Sells Its Connecticut Facility To Winstanley
    • Debt Offering
    • Emisphere Technologies Completes Convertible Notes Offering For $1.27 Million
    • Key Competitors
    • Key Employees
    • Locations And Subsidiaries
    • Head Office
    • Recent Developments
    • Strategy And Business Planning
    • Jun 22, 2009: Emisphere Signs Research Agreement With Syracuse University
    • Financial Announcements
    • Nov 10, 2010: Emisphere Reports Net Income Of $9.6 Million For Q3 2010
    • Aug 16, 2010: Emisphere Reports Net Loss Of $13.7 Million For Q2 2010
    • May 17, 2010: Emisphere Reports Net Loss Of $18.5 Million For Q1 2010
    • Mar 25, 2010: Emisphere Reports Net Loss Of $7.6 Million For Q4 2009
    • Nov 09, 2009: Emisphere Reports Net Loss Of $4 Million For Q3 2009
    • Aug 11, 2009: Emisphere Reports Net Loss Of $3.7 Million For Q2 2009
    • May 07, 2009: Emisphere Reports Net Loss Of $5.1 Million For Q1 2009
    • Mar 10, 2009: Emisphere Reports Net Loss Of $7.7 Million For Q4 2008
    • Nov 06, 2008: Emisphere Technologies, Inc. Announces 2008 Third Quarter Financial Results
    • Aug 11, 2008: Emisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results
    • May 07, 2008: Emisphere Technologies, Inc. Announces 2008 First Quarter Financial Results
    • Mar 17, 2008: Emisphere Technologies, Inc. Announces 2007 Fourth Quarter And Year End Financial Results
    • Nov 06, 2007: Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
    • Aug 07, 2007: Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
    • May 04, 2007: Emisphere Technologies Announces 2007 First Quarter Financial Results
    • Feb 27, 2007: Emisphere Technologies, Inc. Announces Fourth Quarter And Year End Financial Results For 2006
    • Nov 09, 2006: Emisphere Technologies Announces 2006 Third Quarter Financial Results
    • Aug 08, 2006: Emisphere Technologies Announces 2006 Second Quarter Financial Results
    • May 05, 2006: Emisphere Technologies Announces 2006 First Quarter Preliminary Financial Results
    • Mar 14, 2006: Emisphere Technologies, Inc. Announces Fourth Quarter And Year End Financial Results For 2005
    • Nov 10, 2005: Emisphere Technologies Provides 2005 Third Quarter Update
    • Aug 04, 2005: Emisphere Technologies Announces 2005 Second Quarter Results
    • May 10, 2005: Emisphere Technologies Announces First Quarter Financial Results For 2005
    • Feb 15, 2005: Emisphere Technologies Announces Fourth Quarter And Year End Financial Results For 2004
    • Nov 04, 2004: Emisphere Technologies Announces 2004 Third Quarter Preliminary Results
    • Aug 04, 2004: Emisphere Technologies Announces 2004 Second Quarter Results
    • May 06, 2004: Emisphere Technologies Announces First Quarter Financial Results For 2004
    • Feb 19, 2004: Emisphere Technologies Announces Fourth Quarter And Year End Financial Results For 2003
    • Nov 12, 2003: Emisphere Announces Third Quarter Financial Results For 2003
    • Aug 12, 2003: Emisphere Announces Second Quarter Financial Results For 2003
    • May 08, 2003: Emisphere Technologies Announces First Quarter Financial Results For 2003
    • Nov 06, 2002: Emisphere Technologies Reports Results For Third Quarter Of 2002
    • Aug 06, 2002: Emisphere Technologies Reports Results For Second Quarter Of 2002
    • Feb 06, 2002: Emisphere Technologies Announces Fourth Quarter And Year End Financial Results For 2001
    • Oct 25, 2001: Emisphere Technologies Announces Third Quarter Results For 2001
    • Jul 26, 2001: Emisphere Technologies Announces Second Quarter Results For 2001
    • May 01, 2001: Emisphere Technologies Announces First Quarter Results For 2001
    • Feb 14, 2001: Emisphere Technologies Announces Financial Results For The Five Months Ended December 31, 2000
    • Dec 07, 2000: Emisphere Technologies Announces Fiscal 2001 First Quarter Results - Provides Update On Oral Heparin Phase Iii Trial
    • Sep 14, 2000: Emisphere Technologies, Inc. Announces Fiscal 2000 Fourth Quarter And Year End Results
    • Jun 06, 2000: Emisphere Technologies, Inc. Announces Fiscal 2000 Third Quarter And Nine Month Results
    • Mar 16, 2000: Emisphere Technologies, Inc. Announces Fiscal 2000 Second Quarter And Six Months Results
    • Corporate Communications
    • Nov 05, 2009: Emisphere Technologies Appoints Tim Rothwell To Board
    • Jun 08, 2009: Emisphere Technologies Receives NASDAQ Panel Decision
    • May 19, 2009: Emisphere Technologies Appoints Franklin Berger To Board
    • Product News
    • Dec 12, 2005: Emisphere Technologies, Inc. Announces The Presentation Of Positive Results From A Clinical Study Conducted By Independent Investigators Using Oral Salmon Calcitonin In Osteoarthritis Patients
    • Dec 10, 2009: Emisphere Technologies Reports Dmc Recommendation To Proceed With Phase 3 Clinical Trials With Oral Calcitonin For Osteoporosis And Osteoarthritis
    • Nov 29, 2001: Emisphere Announces Clinical Results From First Oral Cromolyn Study
    • Nov 07, 2005: Emisphere Provides Update On Phase Iii Oral Heparin Trial Design
    • Oct 30, 2006: Emisphere Technologies Demonstrates Safety And Efficacy Of Oral Insulin In Phase 2 Trial In Type 2 Diabetics
    • Oct 21, 2008: Emisphere Announces Initiation Of Second Phase Iii Study For Oral Osteoarthritis Treatment
    • Oct 20, 2009: Emisphere Declares Results For PTH1-34
    • Oct 15, 2009: Study Results Suggest Oral Salmon Calcitonin Using Eligen(R) Drug Delivery Technology May Reduce Cartilage And Bone Degradation In Osteoarthritis
    • Oct 14, 2008: Study Finds Improved Absorption Of Oral Salmon Calcitonin Versus Nasal Administration
    • Oct 08, 2009: Emisphere Technologies Introduces First Commercially Available Product, Oral Eligen(R) B12
    • Oct 01, 2008: Emisphere Announces Publication Of Independent Early-Stage Clinical Study On The Effects Of Oral Glp-1 And Pyy3-36 On Glucose And Insulin Concentrations
    • Sep 22, 2008: Emisphere Announces Recruitment Phase Iii Study For Oral Osteoarthritis Treatment
    • Sep 22, 2003: Emisphere Announces Oral Salmon Calcitonin Phase Iia Data Are Presented By Novartis At The American Society For Bone And Mineral Research Annual Meeting
    • Sep 19, 2005: Emisphere Technologies Completes Dosing In Heparin Clinical Trial
    • Sep 17, 2010: Emisphere Reports Positive Clinical Results For SNAC In Appetite Suppression Study
    • Sep 08, 2009: Emisphere Technologies Announces Publication In Clinical Pharmacology And Therapeutics Of Encouraging Data From An Independent Clinical Study Of An Oral Eligen-Glp-1 Formulation On Glucose Homeostasis
    • Sep 08, 1999: Emisphere Technologies, Inc. Announces Start Of Clinical Trials With Novartis Compound
    • Sep 04, 2001: Emisphere To Broadcast Oral Insulin Data At Investor Day
    • Sep 03, 1998: Lilly And Emisphere Announce Osteoporosis Compound To Enter Clinical Trials
    • Aug 24, 1999: Emisphere Technologies, Inc. Announces Phase Ii Clinical And Nonclinical Data Support Moving Forward Into Phase Iii Development
    • Aug 19, 1999: Results Of Emisphere Technologies, Inc. Phase Ii Patient Trial Were Presented Today At The Xviith Congress Of The International Society Of Thrombosis And Haemostasis And Showed Oral Heparin To Be Comparable In Safety And Activity To Subcutaneous Heparin
    • Aug 17, 1999: Emisphere Technologies, Inc. Announces The Presentation Of Its Phase Ii Oral Heparin Results
    • Aug 05, 2008: Emisphere Announces Recruitment Of Novartis Phase Iii Study For Oral Osteoporosis Treatment
    • Aug 05, 1998: Emisphere And Elan Contribute $10 Million To Heparin Joint Venture
    • Aug 04, 2004: Emisphere Technologies Selects Formulation Of Oral Heparin Following Successful Clinical Study
    • Aug 02, 2001: Emisphere Technologies Announces Promising Pre-Clinical Study Results For Oral Treatment Of Osteoporosis
    • Aug 01, 2002: Emisphere Technologies Initiates Human Testing For Oral Human Growth Hormone Program
    • Jul 16, 2010: Emisphere Technologies Provides Update On High Dose Oral Eligen(R) B12
    • Jul 08, 2008: Emisphere Announces Data From Independent Clinical Study Of Effects Of Oral Glp-1 On Glucose And Insulin Concentrations
    • Jul 05, 2005: Emisphere Announces First Milestone In Roche Collaboration
    • Jun 16, 2004: Emisphere Technologies Commences U.S. Clinical Trial To Select New Oral Formulation Of Heparin
    • Jun 16, 2003: Promising Emisphere Oral Insulin Data From Two Key Clinical Studies Is Presented At The American Diabetes Association Annual Meeting
    • Jun 14, 2001: Emisphere Receives Patent Covering Oral Parathyroid Hormone Composition With Lilly
    • Jun 07, 2000: Emisphere Technologies, Inc. Publishes Efficacy Results From Two Preclinical Evaluations Of Oral Heparin And Lmwh In Dvt Treatment
    • Jun 01, 2009: Emisphere Technologies Announces The Completion Of Enrollment In Second Phase Iii Study For Oral Osteoarthritis Treatment Utilizing Proprietary Eligen(R) Technology
    • May 27, 1998: Emisphere Announces Initiation Of Phase Ii Clinical Trial For Oral Heparin Product
    • May 26, 2009: Emisphere Technologies Reports Encouraging Data From Independent Clinical Study Assessing The Effects Of Oral Glp-1 And Pyy3-36, Combined With Eligen(R) Technology On Appetite Suppression
    • May 24, 2007: Emisphere Announces Initiation Of Phase Iii Clinical Program Of Oral Calcitonin For The Treatment Of Osteoarthritis
    • May 21, 2009: Emisphere Technologies Receives Milestone Payment From Mannkind Corporation
    • May 20, 1998: Emisphere Announces New Senior Vice President Of Clinical Affairs
    • May 14, 2002: Emisphere Technologies Reports Results From Phase Iii Oral Heparin Protect Trial
    • May 08, 2003: Emisphere Initiates U.S. Clinical Studies For An Oral Insulin Candidate
    • May 08, 2001: Emisphere Completes Phase I Clinical Testing Of Heparin Tablets
    • May 04, 1998: Emisphere Announces $13.5 Million Private Placement
    • Apr 29, 2010: Emisphere Reports Interim Data From Oral Eligen B12 Study
    • Apr 26, 2010: Emisphere Announces Publication Of Research Describing Growth Promoting Effects Of Calcitonin On Cartilage In Patients With Osteoarthritis
    • Apr 26, 2006: U.S. Federal District Court In Indianapolis Orders Eli Lilly To Assign Intellectual Property To Emisphere
    • Apr 19, 2000: Emisphere Technologies, Inc. Announces Preliminary Results From First Clinical Evaluation Of Oral Heparin Capsule Dosage Form
    • Apr 15, 2010: Emisphere Partner Initiates Second Phase I Trial For Oral Pth Therapy For The Treatment Of Postmenopausal Osteoporosis
    • Apr 12, 2006: Emisphere Provides Update On Use Of The Eligen(R) Technology To Enhance Pulmonary Delivery Of Proteins, Including Insulin
    • Mar 31, 2006: Emisphere Reports Results Of Study Comparing Its Oral Heparin Formulation To Traditional Injectable Heparin
    • Mar 16, 2000: Emisphere Technologies, Inc. Initiating Clinical Testing Of Heparin Solid Oral Dosage Form
    • Mar 09, 2000: Emisphere Technologies Establishes Collaboration With Regeneron Pharmaceuticals For Oral Delivery Of A Protein To Treat Obesity
    • Mar 06, 2003: Emisphere Technologies Announces Favorable Preliminary Patient Data From Oral Insulin Mealtime Study
    • Feb 27, 2007: Initiation Of Phase Iii Program Using Emispheres Eligen(R) Technology For Oral Salmon Calcitonin
    • Feb 26, 2003: Emisphere Technologies Announces Positive Data From A Phase Ii Study Of The Oral Administration Of The Peptide Calcitonin
    • Feb 25, 1999: Emisphere Announces Update On Oral Heparin Development Program
    • Jan 29, 2004: Emispheres Oral Insulin Tablet Multi-Dose Data Indicate Desired Activity With No Observed Hypoglycemic Events
    • Jan 14, 1998: Emisphere And Elan Announce Successful Completion Of Additional Clinical Trials For Oral Heparin Preparation; Joint Venture Will Also Develop Oral Low Molecular Weight Heparin Product
    • Jan 13, 2010: Novo Nordisk Starts Phase I Trial With Long-Acting Oral Glp-1 Analogue
    • Jan 11, 2000: Novartis And Emisphere Technologies Announce Successful Oral Delivery Of A Protein (Calcitonin)
    • Jan 11, 1999: Emisphere And Elan Announce Positive Phase Ii Clinical Trial Results For Oral Heparin Product
    • Jan 08, 2001: Novartis Files Ind For Oral Salmon Calcitonin Utilizing Emispheres Oral Drug Delivery Technology
  • Appendix
    • Methodology
    • About GlobalData
    • Contact Us
    • Disclaimer 136
  • List of Tables
    • Emisphere Technologies, Inc., Pharmaceuticals & Healthcare, Key Facts, 2009
    • Emisphere Technologies, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
    • Emisphere Technologies, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011
    • Emisphere Technologies, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2005 to YTD 2011
    • Emisphere Technologies, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2005 to YTD 2011
    • Emisphere Technologies, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
    • Emisphere Technologies, Inc., Pharmaceuticals & Healthcare Deals By Type, 2005 to YTD 2011
    • Emisphere Technologies, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011
    • Emisphere Technologies, Inc., Deals By Therapy Area, 2005 to YTD 2011
    • Emisphere Technologies, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Emisphere Technologies, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Emisphere Technologies, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Emisphere Technologies, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Therapy Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Emisphere Technologies, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Emisphere Technologies, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Emisphere Technologies, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Emisphere Technologies, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Emisphere Technologies, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Emisphere Technologies, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Emisphere Technologies, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2005 to YTD 2011
    • Emisphere Technologies Enters Into Research Collaboration With Alchemia
    • Emisphere Technologies Enters Into Co-Development Agreement With AAIPharma
    • Emisphere Enters Into Research and Collaboration Agreement With Roche
    • Emisphere Enters Into Licensing Agreement With Novartis Pharma
    • Emisphere Technologies Enters Into Licensing Agreement With Novo Nordisk
    • Emisphere Technologies Enters Into Licensing Agreement With Novo Nordisk
    • Genta Signs Licensing Agreement With Emisphere Technologies
    • Emisphere Technologies Completes Private Placement Of $3.5 Million
    • Emisphere Technologies Completes Private Placement Of $3.5 Million
    • Emisphere Technologies Completes Registered Direct Offering Of $4 Million
    • Emisphere Technologies Completes Private Placement Of $4 Million
    • Emisphere Technologies Completes Registered Direct Offering Of $7.6 Million
    • Emisphere Completes Private Placement Of $33 Million
    • Emisphere Technologies Completes Private Placement Of $15.74 Million
    • Emisphere Sells Its Connecticut Facility To Winstanley
    • Emisphere Technologies Completes Convertible Notes Offering For $1.27 Million
    • Emisphere Technologies, Inc., Key Employees 40
  • List of Figures
    • Emisphere Technologies, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2005 to YTD 2011
    • Emisphere Technologies, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
    • Emisphere Technologies, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2005 to YTD 2011
    • Emisphere Technologies, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011
    • Emisphere Technologies, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2005 to YTD 2011
+44 20 8816 8548

Ask a question about Emisphere Technologies, Inc. (EMIS) - Pharmaceuticals & Healthcare

Enter the characters you see in the picture below
Captcha